Previous 10 | Next 10 |
2023-09-07 08:43:42 ET Losers: NeuBase Therapeutics ( NBSE ) -25% . Sportsman's Warehouse Holdings ( SPWH ) -23% after Q2 earning release . Palisade Bio ( PALI ) -19% . Yext ( YEXT ) -16% after Q2 earning release . Verint Systems...
2023-09-07 06:10:00 ET 3 Top Tools to Use to Analyze Penny Stocks Penny stocks, often priced below $5 per share, present a unique opportunity for investors looking to diversify their portfolios and tap into the potential of emerging companies. Trading penny stocks has gained signifi...
2023-09-06 15:47:16 ET A Pennsylvania-based %Biotech company captured the attention of the trading community on Wednesday after the company announced the receipt of a $15 million tranche under its non-dilutive ex-US royalty-based financing (the R-Bridge Financing). According to the ...
2023-09-06 12:52:31 ET More on Trevena Seeking Alpha’s Quant Rating on Trevena Historical earnings data for Trevena Financial information for Trevena For further details see: Trevena gets $15M tranche after first commercial sale of OLINVYK in China
$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena’s partner in China New OLINVYK respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3...
TRV045 Demonstrated Statistically Significant Analgesic Effect in Capsaicin-induced Model of Neuropathic Pain in Target Engagement POC Study TMS POC Study Provided Statistically Significant Evidence of CNS Activity of TRV045 on Day 4 as Measured by EEG Power Spectral Analysis No...
2023-08-14 11:13:17 ET Trevena press release ( NASDAQ: TRVN ): Q2 GAAP EPS of -$0.69. Revenue of $3.02M. For further details see: Trevena GAAP EPS of -$0.69, revenue of $3.02M
Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for use in acute and chronic pain advancing with topline data expected 3Q 2023 New res...
CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed...
OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV opioids (n=982) New respiratory data from VOLITION ~200 patient real-wor...
News, Short Squeeze, Breakout and More Instantly...
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing ...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...